摘要
目的:探讨地塞米松预处理对紫杉醇诱导卵巢癌细胞凋亡的影响。方法:应用MTT比色法检测地塞米松对紫杉醇抑制细胞增殖的影响,TUNEL法形态学观察细胞凋亡,流式细胞仪PI单染测定地塞米松预处理对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡及细胞周期的影响。结果:不同浓度地塞米松对紫杉醇抑制SKOV-3细胞增殖有不同程度的拮抗作用,TUNEL分析表明地塞米松预处理后能抑制紫杉醇诱导SKOV-3细胞凋亡,流式细胞仪PI单染法分析表明,用地塞米松预处理后再用紫杉醇组的细胞凋亡率为(5.55±0.53)%,而单用紫杉醇组细胞凋亡率为(13.90±1.62)%,地塞米松进行预处理组细胞凋亡率明显降低(P<0.01),且与细胞周期中G2/M期无关。结论:不同浓度地塞米松对紫杉醇抑制SKOV-3细胞增殖有不同程度的保护作用,地塞米松能够拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡,且与细胞周期中G2/M期无关。
Objective: To investigate the effect of paclitaxel-induced apoptosis in human ovarian cancer cell when pretreated with dexamethasone. Methods: MTT assay was used to examine the effect of paclitaxel inhibited cell proliferation when pretreated with dexamethasone. The cell apoptosis on morphology was detected by TUNEL assay. The percentage of apoptosis of hu man ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone was measured by PIstaining and then analyzed by FCM. Results: Dexamethasone can protect differently the inhibition of SKOV-3 cell proliferation induced by paclitaxel. TUNEL assay showed that dexamethasone inhibited the SKOV3 cell apoptosis induced by paclitaxel. The apoptosis percentage of human ovarian cancer cell line SKOV-3 induced by paclitaxel and pretreated with dexamethasone measured by PI-staining was (5.55 ± 0.53)% . The apoptosis percentage treated only with paclitaxe was (13.90 ± 1.62) %. The apoptosis percentage decreased significantly when pretreated with dexamethasone ( P〈0.01 ). The percentage of cell arrested by PTX in the G2/M phase was no significant difference in paclitaxel in the presence or absence of dexamethasone group (P〉 0. 05). Conclusion: Pretreatment with dexamethasone can protect the inhibion of SKOV-3 cell proliferation induced by paclitaxel . Dexamethasone can inhibit apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel without affecting the ability of paclitaxel to induce mitotic division arrest in the G2/M phase.
出处
《中国临床医学》
2009年第6期929-931,共3页
Chinese Journal of Clinical Medicine
关键词
地塞米松
紫杉醇
卵巢癌
抗凋亡
Dexamethasone
Paclitaxel
Ovarian cancer
Anti- apoptosis